UOC
STLN

UBS O'Connor’s Starling Oncology STLN Stock Holding History

UBS O'Connor’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-339,722
Closed -$656K – 925
2020
Q4 		$656K Hold
339,722
– – 0.01% 462
2020
Q3 		$717K Sell
339,722
-4,653
-1% -$48.3K 0.02% 243
2020
Q2 		$511K Buy
+344,375
New +$3.42M 0.01% 316

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

UBS O'Connor's STLN Position: Q4 2021 in Review

UBS O'Connor sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 499,982 shares — an estimated $4.96M sold.

UBS O'Connor first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $13.8M in Q2 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • UBS O'Connor reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 499,982 Starling Oncology shares in Q4 2021, an estimated $4.96M.
  • UBS O'Connor first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
  • UBS O'Connor's Starling Oncology position peaked at $13.8M in Q2 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.